Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | TK2 | O00142 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705298 | 0.98 | TDP1 (0.39) | TDP1NT5EP2RY14MEN1KMT2A | |
| SCHEMBL707274 | 0.86 | P2RY14 (0.40) | TDP1NT5EP2RY14DUTMMP1 | |
| SCHEMBL6360279 | 0.86 | DUT (0.38) | TDP1NT5EP2RY14DUTMMP1 | |
| SCHEMBL707273 | 0.84 | NT5E (0.41) | TDP1NT5EP2RY14TK2P2RY12 | |
| SCHEMBL6360276 | 0.84 | DUT (0.38) | TDP1NT5EP2RY14MEN1KMT2A | |
| SCHEMBL6361053 | 0.80 | P2RY14 (0.47) | NT5EP2RY14P2RY2TYMP | |
| SCHEMBL705473 | 0.79 | TDP1 (0.32) | TDP1NT5E | |
| SCHEMBL705472 | 0.78 | TDP1 (0.35) | TDP1NT5EP2RY14MEN1KMT2A | |
| SCHEMBL31384626 | 0.78 | TYMP (0.43) | P2RY14DUTP2RY12P2RY2TYMP | |
| SCHEMBL707276 | 0.77 | SLC28A1 (0.47) | TDP1P2RY14MEN1KMT2ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670896-B1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20140357856-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8791083-B2 | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8124745-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | Isis Pharmaceutiacls, Inc. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7696345-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090258931-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| EP-1670896-A4 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ALLERSON CHARLES | 2008-02-14 | — | — | US | disclosed |
| EP-1670896-A2 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050142581-A1 | Microrna as ligands and target molecules | ISIS PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005023995-A2 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023986-A2 | MICRORNA AS LIGANDS AND TARGET MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258931-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | NSUN3, NSUN2, NOP2 | TDP1 952/4885NT5E 704/4885P2RY14 4661/4885 |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | HNRNPC, SNRPE, IGF2BP1 | TDP1 2307/4885NT5E 3913/4885P2RY14 4228/4885 |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | RNGTT, NSUN3, RNMT | TDP1 1131/4885NT5E 405/4885P2RY14 4694/4885 |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | TDP1 2307/4885NT5E 3913/4885P2RY14 4228/4885 |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | TDP1 2307/4885NT5E 3913/4885P2RY14 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.